BridgeBio Pharma EBITDA 2018-2024 | BBIO

BridgeBio Pharma EBITDA for the quarter ending December 31, 2024 was $-0.225B, a 27.77% increase year-over-year.

  • BridgeBio Pharma 2024 EBITDA was -0.587B, a 2.33% decline from 2023.
  • BridgeBio Pharma 2023 EBITDA was -0.601B, a 18.88% increase from 2022.
  • BridgeBio Pharma 2022 EBITDA was -0.505B, a 11.45% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

BridgeBio Pharma EBITDA 2018-2024 | BBIO

  • BridgeBio Pharma 2024 EBITDA was -0.587B, a 2.33% decline from 2023.
  • BridgeBio Pharma 2023 EBITDA was -0.601B, a 18.88% increase from 2022.
  • BridgeBio Pharma 2022 EBITDA was -0.505B, a 11.45% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$19.4B
Dr Reddy's Laboratories (RDY)$11.2B
Bausch Health Cos (BHC)$2.4B
Supernus Pharmaceuticals (SUPN)$1.9B
Amphastar Pharmaceuticals (AMPH)$1.5B
Personalis (PSNL)$412M
Taysha Gene Therapies (TSHA)$336M
Assembly Biosciences (ASMB)$81M
Sol-Gel Technologies (SLGL)$16M
Evoke Pharma (EVOK)$8M
Teligent (TLGT)$0M